Compare Expedia Group Inc (EXPE) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Expedia Group (EXPE) trades at $273.44, up 1.85% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with consistent earnings beats, 90% gross margins, and improving cash flow generation. Recent news highlights competitive threats from AI shopping agents but also strong B2B booking growth outpacing peers. Analyst consensus remains divided with a $335 price target representing 22% upside potential.

Expedia presents a compelling growth story with solid execution but faces significant AI disruption risks. The stock offers attractive valuation multiples and strong profitability metrics, though competitive pressures from Meta's Muse AI agent and ongoing layoffs create near-term uncertainty. Institutional positioning remains mixed with recent downgrades offset by positive earnings momentum.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.